Emergent BioSolutions Announces Agreement to Settle Securities Class Action LitigationGlobeNewsWire • 09/13/24
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for EbolaGlobeNewsWire • 09/12/24
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial ProfileGlobeNewsWire • 09/03/24
Emergent BioSolutions Stock Storms Higher After The FDA Signs Off On Mpox VaccineInvestors Business Daily • 08/30/24
Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency PreparednessGlobeNewsWire • 08/30/24
Mpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox InfectionBenzinga • 08/30/24
Emergent BioSolutions' ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other RegionsGlobeNewsWire • 08/29/24
Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora PharmaceuticalsGlobeNewsWire • 08/20/24
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in AfricaGlobeNewsWire • 08/19/24
Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine ApprovalSeeking Alpha • 08/18/24
SERB Pharmaceuticals strengthens leadership in medical countermeasures with the global acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit for $75 millionGlobeNewsWire • 07/31/24
Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 MillionGlobeNewsWire • 07/31/24
Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay' Public Education Campaign Starring Pro Football Hall of Famer Emmitt SmithGlobeNewsWire • 07/24/24